Based on the fact that Dex-treated Tregs express higher levels of cytotoxic T lymphocyte antigen-4 (CTLA-4) [81], which play a role in the inhibitory action of Tregs, all those studies strengthen the possibility of a combined strategy of autoimmune disease therapy with Dex and IL-2, depending on synergistic anti-inflammatory and immunosuppressive effects of both therapeutics. Here, IL2 is linked to autoimmune disease.